Previously, CMS determined that coverage for patients receiving treatment was dependent on their being enrolled in a CMS-approved clinical trial under coverage with evidence development (CED).

A new study shows artificial intelligence (AI) algorithms can more rapidly and objectively determine calcium scores in CT and PET/CT images than physicians.

A new risk analysis suggests the exam will increasingly result in tumor upstaging among high-risk patients.

The biggest news from the American Society of Nuclear Cardiology (ASNC) 2022 meeting was positive late-breaking data on the phase 3 Aurora trial for the flurpiridaz (F-18) PET radiotracer agent.

FDG-PET scans in these patients allow clinicians to determine whether the tumors are still viable or not, thus playing a significant role in making treatment decisions.

Here are the most popular stories on Health Imaging in August, based on our website analytics. 

Adoption of PSMA-PET has been swift because it can significantly improve prostate cancer detection and treatment. SNMMI President Munir Ghesani, MD, explains how.

Munir Ghesani, MD, president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and system chief of nuclear medicine at Mount Sinai Health, explains PSMA-PET has seen rapid adoption because it can significantly improve prostate cancer detection and treatment.